Hybrid Triboelectric-Electromagnetic Magnetic Energy Harvester-Based Sensing for Wireless Monitoring of Transmission Lines.

Magnetic energy is an abundant and persistent form of energy radiating from various sources. Here, a hybrid triboelectric-electromagnetic magnetic energy harvester (HMEH) system consisting of a modified pendulum unit is proposed, interacting mechanically with two multilayered TENGs and remotely with Cu coils. Systematic studies are conducted on magneto-mechano-energy conversion from power transmission lines. The pendulum is made out of a thin PET plate, with two permanent magnets stuck at each side of the free end of the PET plate. Two multilayered TENGs (each of which has one layer fixed at the same angle while other layers are set free) are located at both sides of the pendulum unit. The coils and the magnets make up the electromagnetic generator (EMG). Multilayered TENGs are connected in parallel with the EMG (each unit is connected to an independent rectifying bridge), and it is possible to charge a 100 µF capacitor to 4.78 V within 55 s. The HMEH system is used to power up a thermometer continuously via a 47 µF capacitor. Furthermore, a design for a wireless early warning system for potential fire hazards due to overheating is realized, revealing potential applications for self-powered wireless monitoring of transmission lines.

Pendular-Translational Hybrid Nanogenerator Harvesting Water Wave Energy.

Shore-based water wave energy produced by the impact of ocean waves on the coastline is a kind of clean and renewable energy. In this paper, a pendular-translational hybrid nanogenerator (PT-HNG) with two multilayer triboelectric nanogenerators and a spring base is proposed to harvest the wave energy. Pendular-translational movement mechanism is a sliding rail structure embedded with a permanent magnet, and the output is greatly improved compared to the previous pendular-pendular movement mechanism. Furthermore, the use of the spring base not only makes the device easy to install and fix but also increases the swing angle, which can better harvest the water wave energy. When the PT-HNG is used on the beach, a 33 µF capacitor can be charged to 4.3 V in 85 s. PT-HNG can be used to build self-powered wireless sensor networks to monitor the surrounding environment. This work proposes an innovative and efficient way to capture shore-based wave energy.

Integrated All-Fiber Electronic Skin toward Self-Powered Sensing Sports Systems.

The development of wearable electronic skins (E-skins) requires devices with high flexibility, breathability, and antibacterial activity, as in sports sensing technology. Here, we report a flexible, breathable, and antibacterial triboelectric nanogenerator (TENG)-based E-skin for self-powered sensing in volleyball reception statistics and analytics, which is fabricated by sandwiching a silver nanowire (Ag NW) electrode between a thermoplastic polyurethane (TPU) sensing layer and a poly(vinyl alcohol)/chitosan (PVA/CS) substrate. Benefiting from an outstanding breathability of 10.32 kg m-2 day-1 and biocidal properties of CS and Ag NW, the E-skin offers excellent thermal-moisture comfort and a remarkable antibacterial effect on Escherichia coli and Staphylococcus aureus. A pressure sensitivity of 0.3086 V kPa-1 is demonstrated in the sensing range of 6.65-19.21 kPa. Besides, a volleyball reception statistical and analytical system is further developed based on a 2 × 3 E-skin array. According to this work, the integration of wearable electronic devices with self-powered sensors may expand practical applications in sports.

Risk of severe pulmonary embolism in cancer patients receiving bevacizumab: Results from a meta-analysis of published and unpublished data.

To evaluate the association between severe pulmonary embolism events and bevacizumab, we conducted the first meta-analysis evaluating the incidence and risk of pulmonary embolism associated with bevacizumab-based therapy. We searched PubMed, EMBASE, Cochrane Library, and ClinicalTrials.gov up to September 2016 for randomized controlled trials comparing bevacizumab with no bevacizumab on cancer patients. Incidence rates, relative risks, and 95% confidence intervals were calculated using fixed- or random-effects models. The primary end point was the association of bevacizumab with pulmonary embolism. Subgroup analyses were performed according to tumor type, dose, and publication status. In total, 23 randomized controlled trials were included. For patients receiving bevacizumab, the overall incidence of severe pulmonary embolism events was 1.76% (95% confidence interval = 1.25%-2.27%). Cancer patients treated with bevacizumab did not increase the risk of pulmonary embolism events (relative risk = 1.00, 95% confidence interval = 0.80-1.25). No significant differences in pulmonary embolism incidence or risk among subgroup analyses were observed. No evidence of publication bias was observed. This study suggested that bevacizumab may not increase the risk of pulmonary embolism in cancer patients.

MiR-4673 Modulates Paclitaxel-Induced Oxidative Stress and Loss of Mitochondrial Membrane Potential by Targeting 8-Oxoguanine-DNA Glycosylase-1.

BACKGROUND: Our previous study identified a novel microRNA, miR-4673, which is upregulated in A549 cells exposed to paclitaxel (PTX). In this study, we investigated the role of miR-4673 in PTX-induced cytotoxicity. METHODS: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay, apoptosis assay, 5,5',6,6'-Tetrachloro-1,1',3,3'-tetraethyl-imidacarbocyanine iodide (JC-1) staining and 2',7'-Dichlorofluorescein (DCFH) staining were used to evaluate cell viability, apoptosis, mitochondrial membrane potential (MMP) loss and reactive oxygen species (ROS) generation in A549 and H1299 cells. Bioinformatics analysis and Luciferase reporter assay were used to explore whether 8-oxoguanine-DNA glycosylase-1 (OGG1) is a target gene of miR-4673. RESULTS: Enforced expression of miR-4673 decreased cell viability and increased PTX-induced apoptosis, MMP loss and reactive oxygen species (ROS) generation in A549 and H1299 cells. Bioinformatics analysis, which was used to identify potential target of miR-4673, revealed a binding site of miR-4673 in 3'UTR of OGG1. Luciferase reporters assays showed that miR-4673 specifically binds to 'CUGUUGA' in 3'UTR of OGG1. Enforced expression of miR-4673 decreased accumulation of OGG1. In addition, silencing OGG1 enhanced inhibitory effects of PTX on apoptosis, MMP loss and ROS generation, which is similar to effects of miR-4673. Moreover, enforced expression of OGG1 compromised promoting effects of miR-4673 on PTX-induced apoptosis, MMP loss and ROS generation. CONCLUSION: miR-4673 modulates PTX-induced apoptosis, MMP loss and ROS generation by targeting OGG1.

Adenovirus-Mediated E2F-1 Gene Transfer Augments Gemcitabine-Induced Apoptosis in Human Colon Cancer Cells.

BACKGROUND: E2F-1 is a transcription factor that stimulates cellular proliferation and cell cycle progression. E2F-1 alone is sufficient to stimulate cells to initiate DNA synthesis, and this unscheduled entry into S phase is a potent trigger of apoptosis. Gemcitabine, a novel pyrimidine analogue with structural and metabolic similarities to cytarabine, also can efficiently induce apoptosis, especially for cancer cells that are already in S phase. Gemcitabine has established antitumor activity against solid tumors, including head and neck, ovarian, and non-small cell lung cancers. Therefore, we hypothesized that exogenous E2F-1 expression could accumulate cells in the S phase and thus sensitize them to gemcitabine. METHODS: We constructed an adenoviral vector (AdCMVE2F-1) to transduce the exogenous E2F-1 gene into human cancer cells. Infection of human colon cancer cells with AdCMVE2F-1 resulted in the overexpression of E2F-1 mRNA and protein in a dose-dependent manner and consequently induced accumulation in S phase as measured by FACS analysis. To assess the synergistic antitumor effect of AdCMVE2F-1 and gemcitabine, the human colon cancer cel lines SW620, DLD-1, and LoVo were infected with AdCMVE2F-1 at various multiplicities of infection and then exposed to various concentrations of gemcitabine 24 hours after infection. RESULT: Isobologram analysis showed that E2F-1-transduced cancer cells exhibited higher sensitivity to gemcitabine treatment compared to control virus-infected cells. Treatment with AdCMVE2F-1 plus gemcitabine enhanced endogenous p53 expression in LoVo cells, which contain wild-type p53; however, the finding that the synergistic effect can also be observed in mutant p53-expressing SW620 and DLD-1 cells suggests that wild-type p53 function may not be necessary for the therapeutic effects of this drug combination. Conclusions: Our data demonstrate that overexpression of ectopic E2F-1 protein may render cels more sensitive to gemcitabine-mediated apoptosis, an outcome that has important general implications for the treatment of human cancer.